The Manufacturers Life Insurance Company acquired a new stake in OmniAb, Inc. (NASDAQ:OABI – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 39,103 shares of the company’s stock, valued at approximately $147,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hartline Investment Corp purchased a new stake in OmniAb in the first quarter valued at approximately $54,000. Catalina Capital Group LLC acquired a new stake in shares of OmniAb in the first quarter valued at $69,000. Towerview LLC raised its holdings in shares of OmniAb by 42.9% in the 1st quarter. Towerview LLC now owns 250,000 shares of the company’s stock valued at $1,355,000 after buying an additional 75,000 shares during the period. Isthmus Partners LLC lifted its stake in OmniAb by 23.9% during the 1st quarter. Isthmus Partners LLC now owns 384,998 shares of the company’s stock worth $2,087,000 after acquiring an additional 74,224 shares in the last quarter. Finally, Bleakley Financial Group LLC boosted its holdings in OmniAb by 80.9% during the 1st quarter. Bleakley Financial Group LLC now owns 34,250 shares of the company’s stock valued at $186,000 after acquiring an additional 15,321 shares during the period. 72.08% of the stock is currently owned by hedge funds and other institutional investors.
OmniAb Stock Up 0.2 %
Shares of NASDAQ:OABI opened at $4.08 on Friday. The company has a market cap of $479.87 million, a price-to-earnings ratio of -6.38 and a beta of -0.13. OmniAb, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $6.72. The firm’s 50-day simple moving average is $4.19 and its 200-day simple moving average is $4.37.
Analysts Set New Price Targets
OABI has been the topic of several research reports. Benchmark reissued a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Monday, August 19th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a report on Monday, August 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 target price on shares of OmniAb in a report on Friday, August 16th.
Read Our Latest Research Report on OABI
OmniAb Company Profile
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Recommended Stories
- Five stocks we like better than OmniAb
- What is the Euro STOXX 50 Index?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.